GVS advice fostamatinib (Tavlesse®) for the treatment of chronic immune thrombocytopenia
The National Health Care Institute has completed its assessment whether the medicinal product fostamatinib (Tavlesse®) is interchangeable with another product that is included in the Medicine Reimbursement System (GVS). Fostamatinib is indicated for the treatment of chronic immune thrombocytopenia (ITP). The National Health Care Institute advises the Minister to include fostamatinib (Tavlesse®) in the GVS.
Indication for which reimbursement is requested
Fostamatinib is registered for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
Fostamatinib is available as a 100 mg film-coated tablet containing 126.2 mg of fostamatinib disodium hexahydrate. The recommended initial dose of fostamatinib is 100 mg twice daily. The dose can be increased to a maximum dose of 150 mg twice daily.
National Health Care Institute's advice
The National Health Care Institute advises the Minister to include fostamatinib (Tavlesse®) in List 1B of the Health Insurance Regulation, because the treatment has added value as compared to the current standard treatment.